Skip to content

Advertisement

Open Access

Correction to: The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan

  • Nahla Khawaja1,
  • Jawad Abu-Shennar1,
  • Mohammed Saleh2,
  • Said S. Dahbour2,
  • Yousef S. Khader3 and
  • Kamel M. Ajlouni1Email author
Diabetology & Metabolic Syndrome201810:43

https://doi.org/10.1186/s13098-018-0336-3

Received: 11 April 2018

Accepted: 11 April 2018

Published: 18 May 2018

The original article was published in Diabetology & Metabolic Syndrome 2018 10:8

Correction to: Diabetol Metab Syndr (2018) 10:8 https://doi.org/10.1186/s13098-018-0309-6

It has been highlighted that the original article [1], published 21 February 2018, contained some errors in Table 3. This correction article shows the correct version of Table 3 and the changes that were made.
Table 3

The prevalence of peripheral neuropathy among patients with type 2 diabetes mellitus in Jordan according to relevant socio-demographic, clinical and laboratory characteristics

Variables

Peripheral neuropathy

P value

Yes

n = 396

No

n = 607

Gender

0.137

 Male

201 (41.9)

279 (58.1)

 

 Female

195 (37.3)

328 (62.7)

 

Age (year)

< 0.001

 < 50

23 (17.4)

109 (82.6)

 

 50–69

269 (38.9)

423 (61.1)

 

 ≥ 70

104 (58.1)

75 (41.9)

 

Marital status

0.777

 Single/divorced/widowed

52 (40.6)

76 (59.4)

 

 Married

344 (39.3)

531 (60.7)

 

Working status

< 0.001

 Unemployed

175 (50.9)

169 (49.1)

 

 Employed

83 (29.6)

197 (70.4)

 

 Retired

138 (36.4)

241 (63.6)

 

Physical activity

< 0.001

 Regular

29 (31.5)

63 (68.5)

 

 Not regular

72 (25)

216 (75)

 

 No physical activity

295 (47.4)

328 (52.6)

 

Family history of diabetes

0.014

 Present

356 (41)

513(59)

 

 Absent

40 (29.9)

94 (70.1)

 

Regular visit to treating physicians

< 0.001

 Yes

342 (37.3)

575 (62.7)

 

 No

54 (62.8)

32 (37.2)

 

Body mass index (kg/m2)

0.052

 Normal

32 (37.6)

53 (62.4)

 

 Over weight

103 (34.1)

199 (65.9)

 

 Obese

261 (42.4)

355 (57.6)

 

Duration of diabetes (year)

< 0.001

 < 5

29 (8.7)

304 (91.3)

 

 5–11

139 (39)

217 (61)

 

 ≥ 12

288 (72.6)

86 (27.4)

 

Having hypertension

< 0.001

 Yes

374 (43.5)

486 (56.5)

 

 No

22 (15.4)

121 (84.6)

 

Nephropathy

< 0.001

 Yes

65 (69.1)

29 (30.9)

 

 No

331 (36.4)

578 (63.6)

 

Cardiovascular disease

< 0.001

 Yes

210 (54.8)

173 (45.2)

 

 No

186 (30)

434 (70)

 

Dyslipidemia

< 0.001

 Yes

381 (43)

505 (57)

 

 No

15 (12.8)

102 (87.2)

 

Retinopathy

< 0.001

 Yes

132 (67.3)

64 (32.7)

 

 No

264 (32.7)

543 (67.3)

 

Type of treatment

< 0.001

 Insulin only

77 (60.2)

51 (39.8)

 

 Oral hypoglycemia agents only

120 (22.8)

407 (77.2)

 

 Oral hypoglycemia agents and insulin

199 (57.2)

149 (42.8)

 

HbA1c (%)

< 0.001

 Controlled < 7%

96 (22.7)

326 (77.3)

 

 Uncontrolled ≥ 7%

300 (51.6)

281 (48.4)

 
Changes:
  1. 1.

    A labeling error in Table 3 was corrected (Neuropathy status was replaced by Peripheral neuropathy).

     
  2. 2.

    [Without DPN n = 607 (100%)] was replaced by (Yes n = 396).

     
  3. 3.

    [With DPN n = 396 (100%)] was replaced by (No n = 607).

     
  4. 4.

    [Age group (year): (mean ± SD)] was replaced by [Age (year)], and the mean age was removed from the table.

     
  5. 5.

    [Body mass index (BMI) (kg/m2): (mean ± SD)] was replaced by [Body mass index (kg/m2)] and the mean BMI was removed.

     
  6. 6.

    [Duration of diabetes (year): (mean ± SD)] was replaced by [Duration of diabetes (year)] and the mean duration was removed.

     
  7. 7.

    SBP mmHg (mean ± SD) DBP mmHg (mean ± SD) was removed.

     
  8. 8.

    All these were removed TC (mean ± SD), LDL (mean ± SD), HDL (mean ± SD).

     
  9. 9.

    [HbA1C (%): (mean ± SD)] was replaced by [HbA1c (%)], and the mean HbA1c was removed from the table.

     

Notes

Declarations

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
National Center (Institute) for Diabetes, Endocrinology and Genetics (NCDEG), The University of Jordan, Amman, Jordan
(2)
The University of Jordan, Amman, Jordan
(3)
Jordan University of Science and Technology, Irbid, Jordan

Reference

  1. Khawaja N, Abu-Shennar J, Saleh M, Dahbour SS, Khader YS, Ajlouni KM. The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan. Diabetol Metab Syndr. 2018;10:8. https://doi.org/10.1186/s13098-018-0309-6.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement